Overall, our study confirmed that MYO1G promoter methylation and gene expression were predictive biomarkers for immune cell infiltration in the tumor microenvironment, prognosis and immunotherapy response of cutaneous melanoma patients. Here, MYO1G is linked to cutaneous melanoma.